Alpha-GABa receptor modulators for the treatment of cognitive impairment associated with Huntington’s disease (360G-Wellcome-110377_Z_15_A)
Huntington's disease is a fatal genetic disease characterised by a movement disorder that is accompanied by a decline in cognitive function and changes in mood and behaviour. The decline in cognitive function may precede the movement disorder by a decade or more and is a very important component of the functional disability associated with the disease. There is, however, no effective treatment for enhancing cognitive performance in Huntington's. Professor John Atack at the University of Sussex aims to identify novel drugs that can enhance cognitive performance in subjects with Huntington's disease to address a large unmet medical need.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 810920 |
| Applicant Surname | Atack |
| Approval Committee | Internal Decision Panel |
| Award Date | 2017-10-01T00:00:00+00:00 |
| Financial Year | 2017/18 |
| Grant Programme: Title | Seeding Drug Discovery Award |
| Internal ID | 110377/Z/15/A |
| Lead Applicant | Prof John Atack |
| Partnership Value | 810920 |
| Planned Dates: End Date | 2018-09-27T00:00:00+00:00 |
| Planned Dates: Start Date | 2017-10-11T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | South East |